Everyone’s Talking About Peptides. Here’s What’s Known and What Isn’t.
In July, an FDA advisory panel voted 8 to 6 to recommend letting compounding pharmacies make BPC-157 and TB-500, two of the peptides you’ve probably seen pitched for injury recovery. The FDA’s own scientists had recommended against it.
Both sides of the peptide argument were in that room. They’re both in your feed too.
What a peptide is
A peptide is a short chain of amino acids, the same building blocks that make up protein. Your body makes thousands of them, and many work as signals that tell cells what to do. Insulin is one.
The ones sold for fitness are synthetic. BPC-157 is modeled on a fragment of a protein found in human gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a protein found in most of your cells. Both are usually injected, and both are sold on the promise that you’ll heal and recover faster.
Why peptides are suddenly everywhere
The rules changed twice this year.
For years BPC-157, TB-500 and others sat on an FDA list called Category 2. It’s reserved for substances with safety concerns serious enough that compounding pharmacies can’t make them. The FDA put BPC-157 there in 2023, citing concerns about impurities and immune reactions.
In April 2026, the FDA took BPC-157 and 11 other peptides off that list. That didn’t make them approved drugs, and it didn’t make them legal to compound. It left them in a gray zone, and sellers moved in fast.
Then came the July vote. The FDA’s Pharmacy Compounding Advisory Committee reviewed 7 peptides for the 503A bulks list, the list of ingredients compounding pharmacies are allowed to use. It recommended 6. BPC-157, KPV and TB-500 passed 8 to 6 with one abstention, and MOTS-c, Semax and Epitalon passed by similarly narrow margins. FDA staff had recommended against all 7.
The vote is advice. The FDA isn’t bound by it, and adding anything to the list takes formal rulemaking, which usually runs 8 to 12 months. As of late September, none of the 6 had been added. Five more, including GHK-Cu and Melanotan II, go before the same committee by February 2027.
The evidence on BPC-157 and TB-500
The case for BPC-157 is built mostly on animal research. In rats it has sped up healing in tendons, muscle and the gut across dozens of studies, and animal testing hasn’t turned up obvious toxicity at the doses used. That’s why researchers are interested, and it’s why this isn’t a simple scam.
The human evidence is thin. When FDA reviewers looked at it ahead of the July vote, they found 5 BPC-157 trials, all small and short, and concluded they weren’t enough to establish safety or effectiveness for the uses under review. The study cited most often online is a knee pain report with no control group.
Compare that to creatine, which has been studied in people for decades. That’s why the advice on creatine can name who it helps and at what dose. Peptides don’t have that yet. Nobody has measured what happens to people injecting them for months or years at the doses being sold.
People who say a peptide fixed an injury nothing else would are describing something that happened to them. Without a control group, though, nobody can tell how much of the recovery came from the peptide and how much came from time, rest, or whatever else they were doing for it.
What’s in the vial
Most peptides sold online carry a label that says “research use only, not for human consumption.” That wording keeps the seller outside the rules that govern drugs. It also means nobody is checking the product to drug standards, even though some of the same sites publish dosing guides.
Independent testing of grey market peptides has found vials with the wrong amount, the wrong compound, and bacterial contamination. With an injection, contamination is the bigger worry, because it goes straight past the protection your skin and gut normally give you.
A peptide from a compounding pharmacy, prescribed by a doctor, is a different product. It’s made to pharmacy standards for a specific patient. It still isn’t an FDA approved drug, and for BPC-157 the legal route to getting one this way isn’t settled yet.
If you compete
BPC-157 and TB-500 are both on the WADA prohibited list. If you’re in a tested sport, whatever the FDA decides doesn’t change that, and a “research use only” label won’t help you explain a positive test.
Where that leaves you
Neither side has proven its case yet. For BPC-157 and TB-500, nobody knows how well they work in people or what long term use does, and the FDA’s final decision is still months away.
If you’re considering one, the questions that matter are where it came from, who is supervising it, and what you’ll do if it doesn’t work. A vial from a website that says “not for human consumption,” dosed off a stranger’s protocol, carries the most unknowns of any version.
If faster recovery is what you’re after, the options with human trials behind them are less exciting and a lot cheaper. Sleep and protein are two, and so is training volume you can actually recover from, which our hypertrophy guide covers.
